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Poster Session I S257effects included nausea, vomiting, diarrhea, dizziness and lighthead-
edness following doses 1 and 2. The patient underwent AuSCT and
achieved neutrophil engraftment on day +13 and platelet engraft-
ment on day +20.
Observations:Peak concentrations were proportional to dose. AUC
increased over the 3 days suggesting accumulation. Estimated clear-
ance on HD was 3-3.7 fold higher than clearance off HD. Cl/F and
V/F after dose 1 was comparable to published values while T1/2 is
longer. Maximum 40mg dose was effective and tolerated. Plerixafor
and filgrastim stimulated mobilization of HSC in the actively dia-
lyzed patient is feasible, well tolerated and results in adequate num-
bers of functional cells for use in AuSCT.142
LONG TERM ENGRAFTMENT IS ASSOCIATED WITH SURVIVAL AFTER AU-
TOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTI-
PLE MYELOMA
Bains, T., Lemieux, A., Abar, F., Maziarz, R.T., Chen, A.I. Knight Can-
cer Institute- Oregon Health and Science University, Portland, OR
The correlationwith long term engraftment on outcomes after au-
tologous transplantation is largely unknown. We conducted a retro-
spective analysis of 214 patients who underwent auto-SCT for
multiple myeloma from 1990 – 2009 and correlated long term en-
graftment of PBSC autografts (median CD34 dose 4.49; range
1.77-81.96) with outcomes. Patients who receivedmaintenance ther-
apy were not included in this analysis, and patients who relapsed
prior to assessment of engraftment were also excluded. Optimal en-
graftment was defined by NCI CTCAE grade 1 criteria for cytope-
nias (ANC$ 1,500/mm3, platelets$ 75,000/mm3, and hemoglobin
$ 10g/dL). The median age was 57 (range 31-76), and the median
follow-up was 2.9 years. At day 100, 40% of patients achieved opti-
mal engraftment, and 34% of patients had maintained these optimal
engraftment levels at 1 year. There were no significant differences in
gender, age, number of prior therapies, myelotoxic therapies (mel-
phalan, lenalidomide, or radiation), andCD34 dose between patients
with optimal vs sub-optimal engraftment. Cytogenetics and ISS
stage from diagnosis were not available in the majority of patients.
Performance status (KPS\90%) was associated with poor engraft-
ment at day 100 but not 1 year.
Engraftment at day 100 was not associated with outcome. How-
ever, patients with optimal engraftment at 1 year were observed to
have improved 3 year overall survival (89% vs 69%, p 5 0.05) but
not progression free survival (61% vs 62%). In our series, the major-
ity of patients did not achieve optimal long term engraftment after
auto-SCT in myeloma, and there appears to be a correlation of im-
paired long term engraftment with a deleterious effect on overall sur-
vival. Further analysis in larger data sets and other hematologic
malignancies to confirm this finding and to identify factors predictive
of long term engraftment is ongoing.143
PHASE IIA, OPEN-LABEL, RANDOMIZED, PHARMACOKINETIC COMPARA-
TIVE, CROSS-OVER STUDY OF MELPHALAN HCL FOR INJECTION (PRO-
PYLENE GLYCOL-FREE) AND ALKERAN FOR INJECTION FOR
MYELOABLATIVE CONDITIONING IN MULTIPLE MYELOMA PATIENTS
UNDERGOING AUTOLOGOUS TRANSPLANTATION
Aljitawi, O.S.1,2, Ganguly, S.1,2, Abhyankar, S.1,2, Wolfe, K.2,
Daniels, K.2, Ferree, M.3, Marks, R.3, Kramer, W.4, Pipkins, J.D.5,
McGruirk, J.P.1,2 1University of Kansas Medical Center; 2University of
Kansas Cancer Center; 3Clinipace Worldwide; 4Kramer Consulting
LLC; 5CyDex Pharmaceuticals, Inc. (A Ligand Company)
Background: Though high-dose melphalan and autologous trans-
plantation is a standard procedure in transplant eligible multiple my-
eloma patients. Themarketed formulation of melphalan, Alkeran for
Injection (Alkeran), has marginal solubility and limited chemical sta-
bility upon reconstitution. Alkeran uses propylene glycol as a co-sol-
vent, which has been reported to cause complications including renal
dysfunction and arrhythmias. Propylene Glycol-Free MelphalanHCL for Injection (PG-free Melphalan) is a reformulation of Al-
keran. It incorporates Captisol, a specially modified cyclodextrin,
to replace the co-solvents and improve stability. This abstract sum-
marizes the ultimate findings from this study after enrollment of all
planned patients.
Methods: This is a phase IIa, open-label, randomized, cross-over
design bioequivalence study. In this study, both the compartmental
and non-compartmental pharmacokinetics (PK) of PG-freeMelpha-
lan and Alkeran were assessed in the same MM patients undergoing
transplantation. Patients received both drug products in alternating
dosing day fashion and were their own control for PK comparison.
Furthermore, the safety and tolerability of high-dose melphalan
HCL and rates of myeloablation and subsequent engraftment were
determined in all patients.
Results: 24 patients, 11 females and 13males, were enrolled between
2/4/2010 and 05/16/2011 at TheUniversity of KansasMedical Cen-
ter and Cancer Center. All patients achieved myeloablation followed
by successful engraftment. Median time to myeloablation was 6 days
post the start of preparative regimen (range 3-8 days). Median time
to neutrophil engraftment was day +9.5 post transplant (range: 9-
12). No additional toxicities were reported with PG-freeMelphalan.
The following events occurred more frequently ($2 difference)
when Alkeran was given first (edema, headache, dysguesia, rash, bun-
dle branch block,) and the following events occurredmore frequently
($2 difference) when PG-free Melphalan was given first (dizziness).
PK analysis showed PG-free Melphalan was bioequivalent with Al-
keran and also revealed that Cmax and AUC were somewhat higher
after PG-free Melphalan.
Conclusions: PG-free Melphalan resulted in successful myeloabla-
tion and subsequent engraftment with no immediate infusion-re-
lated toxicity and no additional overall transplant-related toxicity.
PG-free Melphalan was bioequivalent to Alkeran while also demon-
strating a marginally higher systemic drug exposure.144
AN INNOVATIVE APPROACH TO AUTOLOGOUS STEM CELL COLLECTION
IN THE PEDIATRIC PATIENT
Peltz, A.C., Law, D.E., Giller, R.H. Children’s Hospital Colorado,
Aurora, CO
Autologous stemcell collection in the pediatric patient can be a chal-
lenging and expensive endeavor. Our institution has created a novel,
systematic procedure that has created a safe and efficient collection.
Using outpatient Interventional Radiology, we place two turbo flow
PICC lines with imaging –guided percutaneous technique centrally
in patients that are greater than 30 kg. In patients under 30 kg, we
are able to use double lumen broviacs or a single turbo flow PICC
and the existing central line (I.e. single lumen mediport or broviac).
Collection then takes place in our outpatient Apheresis Center without
sedation of the patient. We have successfully collected more than 54
pediatric patients, with differing diagnoses, using these methods since
the end of September 2008. We have had no documented line infec-
tions of the temporary PICC lines. This method allows for the pediat-
ric patient to remain an outpatient, with a low morbidity procedure,
but optimizing the stem cell collection process.CLINICAL CELLULAR THERAPY145
THE USE OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS
FOR TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS AND NEU-
RODEGENERATIVE DISORDERS – ACHIEVEMENTS AND FUTURE GOALS
Slavin, S., Brodie, C. International Center for Cell Therapy & Cancer Im-
munotherapy (CTCI), Tel Aviv, Israel; Bar-Ilan University, Ramat-Gan,
Israel
Future treatment of multiple sclerosis (MS) aims at restoringmye-
lination and neurological functions as well as re-induction of self-tol-
erance. We studied the role of mesenchymal stromal stem cells
(MSC), known to be anti-inflammatory on the one hand and
